Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease

M. Annereau, E. Bermudez, F. Lemare, R. P. Desmaris, J. Lazarovici, D. Ghez, E. Solary, S. de Botton, J. B. Micol

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Abstract

    Background Patients diagnosed with therapy-related myeloid neoplasms (TRMN) with concomitant active neoplastic disorder (CAND) are usually proposed for best supportive care (BSC). We evaluated the feasibility of using 5-azacytidine (AZA) in this setting. Methods All patients referred to Gustave Roussy between 2010 and 2015 for TRMN diagnosis (less than 30% blast) and eligible for AZA treatment were included. Patients with CAND proposed for BSC were also described. Patient's outcomes were analyzed based on the presence or not of a CAND. Results Fifty-two patients with TRMN were analyzed, including 19 patients with CAND (14 eligible for AZA) and 33 without CAND eligible for AZA. The 5 patients with CAND ineligible for AZA had a worst performance status (p = 0.016) at diagnosis and a shorter overall survival (OS) (0.62 months). Baseline characteristics of patients eligible for AZA were similar in the 2 groups except a trend for best performance status in patients with CAND (p = 0.06). Overall response rate (71.4% vs 60.3%), transfusion independence (50.0% vs 45.5%) and OS (12.7 months vs 10.8 months) were similar between patients with and without CAND respectively (p = ns). Conclusion Here we report the feasibility and efficacy of AZA for selected patients with TRMN and a CAND.

    Original languageEnglish
    Pages (from-to)58-64
    Number of pages7
    JournalLeukemia Research
    Volume55
    DOIs
    Publication statusPublished - 1 Apr 2017

    Keywords

    • 5-Azacytidine
    • Hypomethylating agents
    • Myeloid leukemias and dysplasias
    • Therapy-related acute myeloid leukemia
    • Therapy-related myelodysplastic syndromes
    • Therapy-related myeloid neoplasms

    Cite this